BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kellie JF, Tran JC, Jian W, Jones B, Mehl JT, Ge Y, Henion J, Bateman KP. Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective. J Am Soc Mass Spectrom 2021;32:1886-900. [PMID: 32869982 DOI: 10.1021/jasms.0c00270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kaur S, Alley SC, Szapacs M, Wilson A, Ciccimaro E, Su D, Henderson N, Chen L, Garofolo F, Hengel S, Jian W, Kellie JF, Lee A, Mehl J, Palandra J, Qiu H, Savoie N, Shakleya D, Staelens L, Sugimoto H, Sumner G, Welink J, Wheller R, Xue YJ, Zeng J, Zhang J, Zhou H, Wang J, Summerfield S, Kavetska O, Dillen L, Ramanathan R, Baratta M, Dasgupta A, Edmison A, Ferrari L, Fischer S, Fraier D, Haidar S, Heermeier K, James C, Ji A, Luo L, Lima Santos GM, Post N, Rosenbaum AI, Sporring S, Surapaneni S, Vinter S, Wan K, Woolf E, Kavetska O, Cho SJ, Kossary E, Prior S, Abhari MR, Soo C, Wang YM, Bandukwala A, Cherry E, Cludts I, Ghosh S, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Maxfield K, Pedras-Vasconcelos J, Saito Y, Smith D, Solstad T, Verthelyi D, Wadhwa M, Wagner L, Waxenecker G, Yan H, Zhang L. 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis 2022;14:505-80. [PMID: 35578993 DOI: 10.4155/bio-2022-0078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sun L, Xu Y, Dube N, Anderson M, Breidinger S, Vaddady P, Thornton B, Morrow L, Matthews RP, Stoch SA, Woolf EJ. Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114639] [Reference Citation Analysis]
3 Wang N, Wang L. Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs. Curr Opin Chem Biol 2021;66:102106. [PMID: 34968810 DOI: 10.1016/j.cbpa.2021.102106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Smith LM, Agar JN, Chamot-Rooke J, Danis PO, Ge Y, Loo JA, Paša-Tolić L, Tsybin YO, Kelleher NL; Consortium for Top-Down Proteomics. The Human Proteoform Project: Defining the human proteome. Sci Adv 2021;7:eabk0734. [PMID: 34767442 DOI: 10.1126/sciadv.abk0734] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
5 Rolland AD, Prell JS. Approaches to Heterogeneity in Native Mass Spectrometry. Chem Rev 2021. [PMID: 34470219 DOI: 10.1021/acs.chemrev.1c00696] [Reference Citation Analysis]
6 Schuster J, Kamuju V, Mathaes R. Assessment of Antibody Stability in a Novel Protein-Free Serum Model. Pharmaceutics 2021;13:774. [PMID: 34067269 DOI: 10.3390/pharmaceutics13060774] [Reference Citation Analysis]
7 Brown KA, Melby JA, Roberts DS, Ge Y. Top-down proteomics: challenges, innovations, and applications in basic and clinical research. Expert Rev Proteomics 2020;17:719-33. [PMID: 33232185 DOI: 10.1080/14789450.2020.1855982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]